NCT01046487 2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1 Completed
Clinical Trials
212 trialsNCT02881086 2025-12-16
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Goethe University
Phase 3 Completed
NCT03578367 2025-11-10
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Novartis
Phase 2 Completed
NCT01316250 2025-10-02
Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
American University of Beirut Medical Center
Phase NA Completed
NCT00476190 2025-06-12
ALL Adult Consortium Trial: Adult ALL Trial
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01085617 2025-03-30
UKALL14
University College, London
Completed
NCT01804985 2025-03-14
DESTINY
University of Liverpool
Phase 2 Completed
NCT04126681 2025-03-03
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Ascentage Pharma Group Inc.
Phase 2 Completed
NCT00483366 2024-09-23
Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors
University of Nebraska
Phase 1 Completed
NCT02326311 2024-08-13
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 3 Completed
NCT02001818 2024-08-06
PInNACLe
Australasian Leukaemia and Lymphoma Group
Phase 2 Completed
NCT01294202 2024-08-02
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT02081378 2024-03-18
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
Novartis
Phase 1 Completed
NCT02260505 2024-01-05
ImadGist
Centre Leon Berard
Phase 3 Completed
NCT02352558 2023-11-14
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT04006769 2023-10-18
Entacapone Combination With Imatinib for Treatment of GIST
Xiangya Hospital of Central South University
Phase EARLY_PHASE1 Completed
NCT00928525 2023-10-05
Basket 1
Italian Sarcoma Group
Phase 2 Completed
NCT00161213 2023-08-14
Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT00764595 2023-07-21
GISTs
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 2 Completed
NCT01593254 2023-06-22
DASCERN
Bristol-Myers Squibb
Phase 2 Completed
NCT00287105 2023-05-24
ESPHALL
Rennes University Hospital
Phase 2 Completed
NCT02712112 2023-01-04
A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
Asan Medical Center
Phase 2 Completed
NCT03609424 2023-01-03
PDR001 Plus Imatinib for Metastatic or Unresectable GIST
Asan Medical Center
Phase 1/2 Completed
NCT01319981 2022-09-27
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03023046 2022-07-13
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
University of Washington
Phase 2 Completed
NCT03170180 2022-06-15
Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer
Samsung Medical Center
Phase 2 Completed
NCT00061945 2022-05-03
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00769327 2022-01-04
CML0408
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT00171223 2021-07-22
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha
Novartis
Phase 2 Completed
NCT00171249 2021-07-22
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia
Novartis
Phase 2 Completed
NCT00171158 2021-06-25
An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis
Novartis
Phase 2 Completed
NCT01275222 2021-06-25
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
Novartis
Phase 1/2 Completed
NCT02130557 2021-05-18
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer
Phase 3 Completed
NCT04883125 2021-05-12
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment
Mansoura University
Phase 2 Completed
NCT02303899 2021-01-22
Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma
Istituto Clinico Humanitas
Phase 2 Completed
NCT01468688 2020-12-21
A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients
Novartis
Phase 1 Completed
NCT00135005 2020-12-08
Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)
Novartis
Phase 1 Completed
NCT00301093 2020-10-28
Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00028002 2020-10-26
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
National Cancer Institute (NCI)
Phase 2 Completed
NCT00137111 2020-09-11
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 3 Completed
NCT00510354 2020-09-10
Radix
Novartis
Phase 4 Completed
NCT00390156 2020-07-28
Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors
University of California, San Francisco
Phase 1 Completed
NCT03131999 2020-06-16
LAMP-1
Medical University of South Carolina
Phase 1/2 Completed
NCT00219739 2020-04-13
SPIRIT
Poitiers University Hospital
Phase 3 Completed
NCT02257541 2020-03-30
BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00509093 2020-03-17
Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00036738 2020-01-29
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00338728 2020-01-27
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01151852 2020-01-14
Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT
Asan Medical Center
Phase 3 Completed
NCT02495519 2020-01-14
A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)
Yonsei University
Phase 2 Completed